OncoCyte Corporation — FY2018 Form 10-K
Filing identity and period: The supplied filing is OncoCyte Corporation’s Form 10-K for the fiscal year ended December 31, 2018, filed April 1, 2019. This does not match the request metadata naming Insight Molecular Diagnostics Inc. or “2018 Q4”; the filing reports full-year results, not standalone fourth-quarter results.
Business context
OncoCyte was a development-stage molecular diagnostics company focused primarily on DetermaVu, a blood-based test intended to help distinguish benign from malignant lung nodules. The company had no commercial diagnostic tests or operating revenue in either 2018 or 2017. It expected to offer DetermaVu as a laboratory-developed test through its CLIA-certified laboratory, subject to further validation and regulatory developments.
Financial performance and position
| Metric | FY2018 | FY2017 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $6.5 million | $7.2 million |
| General and administrative expense | $7.0 million | $9.2 million |
| Sales and marketing expense | $1.7 million | $2.4 million |
| Total operating expenses / operating loss | $15.2 million | $18.8 million |
| Net loss | $15.8 million | $19.4 million |
| Net loss per share | $0.42 | $0.64 |
| Net cash used in operations | $11.6 million | $13.4 million |
- At December 31, 2018, cash and cash equivalents were $8.0 million; marketable equity securities were $0.4 million; total current assets were $8.6 million and current liabilities were $5.6 million.
- Total liabilities were $6.1 million. The balance sheet included $0.8 million of current loan payable, $0.3 million of noncurrent loan payable net of financing costs, and $0.6 million of capital lease liabilities. It also included $2.1 million due to BioTime and affiliates.
- Financing activities provided $12.1 million in 2018, chiefly from equity offerings; cash increased by $0.4 million during the year. Accumulated deficit was $71.3 million.
- In February 2019, after year-end, the company raised $37.4 million net from a public offering and received $0.9 million from option exercises. It reported that available cash and securities were expected to fund operations for at least 12 months from the financial-statement issuance date.
Changes, outlook, and notable items
- Net loss narrowed by about $3.6 million year over year, and operating cash use decreased by about $1.7 million. Lower expenses included the absence of a $4.1 million 2017 noncash charge for warrants issued to induce warrant exercises; 2018 results included a $0.6 million noncash impairment of therapeutic-use intangible assets.
- In January 2019, OncoCyte reported an R&D Validation study of 250 blinded samples with 90% sensitivity (95% CI 82%–95%) and 75% specificity (95% CI 68%–81%). This was an R&D-stage result, not completion of the later validation steps or evidence of commercial performance.
- Management’s 2019 objectives included completing CLIA Laboratory Validation, conducting Clinical Validation, commencing commercialization, and preparing a Medicare coverage dossier. The company targeted commercialization in the second half of 2019, while acknowledging possible delays. Clinical utility studies could take up to three years.
- Management expected spending to rise with validation, laboratory capacity, and sales-force buildout; it did not expect pre-Medicare-reimbursement revenue to cover operating costs. Additional capital would be needed absent sufficient test sales or licensing revenue.
- Key risks include further validation failure or delay, uncertain physician adoption and payer reimbursement, evolving FDA oversight of laboratory-developed tests, reliance on a single laboratory and limited equipment/reagent suppliers, intellectual-property and Wistar-license obligations, and potential shareholder dilution from future financing.
- The company accrued $300,000 in 2018 for liquidated damages related to a late resale-registration filing for a 2018 private placement. Separately, Chardan Capital Markets claimed fees under an engagement letter; OncoCyte disputed the claim, and the filing said the outcome and financial effect could not then be assessed.
- The independent auditor issued an unqualified opinion on the financial statements. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor did not provide an opinion on internal control.
Most important facts to verify
- Confirm the issuer and reporting period: this is OncoCyte’s FY2018 10-K, not an Insight Molecular Diagnostics filing or a standalone Q4 report.
- Check subsequent filings for actual completion and results of DetermaVu’s analytical, CLIA laboratory, and clinical validation, and whether commercialization occurred.
- Track Medicare and private-payer coverage, reimbursement rates, and evidence requirements; the company had no operating revenue at year-end.
- Review cash use, financing needs, dilution, and debt repayment obligations, including the Silicon Valley Bank loan and BioTime-related balances.
- Follow developments in the Chardan claim and the accrued registration-related damages, as well as changes in FDA or legislative requirements for LDTs.